Dr. John Cush RheumNow
1 year 9 months ago
Review of of nurse-led care (NLC) vs Rheum-led (RLC) vs Usual care in RA pts - 14 studies, 3369 pts. shows NLC proves highly effective in managing RA patients, surpassing usual care and equating to rheumatologist-led care in primary and secondary outcomes.… https://t.co/evpFTT9n22 https://t.co/n8ncKG9SFt
Dr. John Cush RheumNow
1 year 9 months ago
Phase 3 Trial Results of Deucravacitinib in Psoriatic Arthritis
Bristol Myers Squibb announced recently the results from POETYK PsA-1 and POETYK PsA-2, Phase 3 trials pivotal trials of deucravacitinib (DEUC) in adults with active psoriatic arthritis (PsA).… https://t.co/yKBV91dR8z https://t.co/nndnpYheNu
Data from a large UK database finds that gout patients starting urate-lowering therapy (ULT) will benefit from added colchicine prophylaxis by having fewer cardiovascular events.
Dr. John Cush RheumNow
1 year 9 months ago
In #RA, Higher levels of ESR and CRP, but not DAS28, joint counts or global assessments, were significantly associated with the risk of incident ILD in RA. German biologics (RABBIT) registry study compared 139 RA-ILD vs vs 686 controls. https://t.co/Ul4HZ1hzS0 https://t.co/GLKL7U4ASt
EULAR has established guidance on best practices for delivering patient education in physical activity and self-management of pain during transitional care in rheumatology.
Dr. John Cush RheumNow
1 year 9 months ago
Leeds study of 19 pts at-risk for RA (ACPA+ & arthralgia) finds low-diversity gut microbiome & in the 10 mos preceding the transition to RA, microbiome becomes more unstable w/ accumulation of Prevotellaceae, particularly Prevotella copri https://t.co/rbYMCl1FcO https://t.co/LWqppg36cn
Dr. John Cush RheumNow
1 year 9 months ago
Benefit of Achieving Target Serum Urate Levels in Gout with Chronic Kidney Disease
A cohort study of gout patients with CKD stage 3 found that lowering serum urate (SUA) level to less than 6 mg/dL, lowered the risk for severe or end-stage kidney disease progression.… https://t.co/NsGUGvb5L5 https://t.co/QPBWA4VqTo
Dr. John Cush RheumNow
1 year 9 months ago
Surveys of US IBD specialty clinic pts (n=699) used SpA screening tools ( DETAIL & IBIS-Q) finding that 27% & 40%, respectively, screened positive, mostly for axial Sxs. In screen pos pts, 31% had a prior Rheum Dx or saw a rheumatologist in the year. https://t.co/1qlAl5xVfV https://t.co/HEwdLpgx2R
Dr. John Cush RheumNow
1 year 9 months ago
12 mos study of RCT 179 gout pts starting allopurinol finds that betw mos 6-12, gout flares went down. 38% had no flares, 19% had 1 flare, & 43% had >1 flare in 2nd 6 mos. # flares equates to control and impact of gout on outcomes. https://t.co/TMwXZStbJU
Dr. John Cush RheumNow
1 year 9 months ago
nline, lifestyle intervention program shown to have positive long-term effects in 264 patients w/ Inflam Arthritis, OA & FM , even after 2-yrs. Prg focused on nutrition, exercise, relaxation & sleep. Signif reductions in Wt, BMI, and PRO's (pain, Am stiff, fatigue)… https://t.co/ImNzTZGLut https://t.co/rAn8llwnjP
An epidemiologic assessment of the prevalence of autoimmune diseases in the United States (US) finds that nearly 5% of the population has an autoimmune disorder, twice as many in women compared to men.
Dr. John Cush RheumNow
1 year 9 months ago
Data from Psoriasis Atherosclerosis and Cardiometabolic Disease Initiative & Stockholm Psoriasis Cohort (n=769 Pso Pts) finds that PsO severity (PASI) PASI assoc w/ GlycA levels (syst inflammation) & GlycA levels assoc w/ CVD risk (OR=1.23) https://t.co/IwUHILMpnI https://t.co/DnEF3yuTvg
Dr. John Cush RheumNow
1 year 9 months ago
UKs University of Birmingham researchers have just been awarded £3.5 million funding from Johnson & Johnson to investigate mechanisms of response and non-response to biologic and targeted synthetic therapies in rheumatoid arthritis. https://t.co/or9amYqljz https://t.co/EvDhVfqOig
Dr. John Cush RheumNow
1 year 9 months ago
RheumNow Live 2025 kicks off in just 6 weeks! Join us Feb 8-9 in Dallas for an unmatched rheumatology event.
https://t.co/VH2ahP1XUy
Don’t miss expert insights on JAK Inhibitors from:
🔹 Madelaine Feldman, MD
🔹 Joseph F. Merola, MD
🔹 Christina Charles-Schoeman, MD… https://t.co/9dRVwLNufF https://t.co/r88g6QMBC3
The antiviral drug valaciclovir (Valtrex), given prophylactically, kept patients with systemic lupus erythematosus (SLE) under treatment with anifrolumab (Saphnelo) from having herpes zoster attacks, researchers said, offering a potential alternative to zoster vaccination.
